Flerie Q3 net loss more than doubles to SEK 281 million

Bitget2026/10/15 06:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Flerie’s net loss more than doubled to SEK 281 million in its January–September 2026 interim report.
Net asset value fell 21% year over year to SEK 3.11 billion; portfolio shares’ total fair value dropped 12% to SEK 2.73 billion.
During the quarter, portfolio company Empros Pharma’s net asset value was written down in full.
Shareholders approved the Biosergen merger plan, with completion expected in October.
Egetis Therapeutics received FDA approval for EMCITATE; Xspray Pharma received an FDA complete response letter for Dasynoc.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Flerie AB published the original content used to generate this news brief on October 15, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.

华尔街见闻•2026/11/08 12:41